Atirmociclib

Phase 2Small molecule

Pfizer

Atirmociclib is one of 120 small molecule programs targeting Advanced Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

119

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced CancerActive, not recruiting

Advanced Breast CancerRecruiting

Metastatic Breast CancerRecruiting

Hepatic ImpairmentRecruiting

Advanced CancerPhase 1

Active, not recruiting

Advanced Breast CancerPhase 2

Recruiting

Metastatic Breast CancerPreclinical

Recruiting

Hepatic ImpairmentPhase 1

Recruiting

Competition

Competitive Landscape

67 competitors in Advanced Cancer

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

12 2

Taxol

Teva

Phase 2

12 3

Gemzar

Johnson & Johnson

Phase 2

8 4

Camptosar

Pfizer

Phase 2

8 5

Opdivo

Bristol-Myers Squibb

Phase 2

6 6

Verzenio

Eli Lilly

Phase 2

4 7

Elunate

Takeda

Phase 2

1 8

Taxotere

AAvyxa

Phase 2

9 9

Paraplatin

AAvyxa

Phase 2

5 10

Torisel

PPrism Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Active, not recruiting

Advanced Cancer

NCT06239467

Phase 1Recruiting

Hepatic Impairment

NCT07677358

Q4 2027

Phase 2Recruiting

Advanced Breast Cancer

NCT07427394

Q1 2028

Phase 1Active, not recruiting

Metastatic Breast Cancer

NCT05508906

Q3 2030

PreclinicalRecruiting

Metastatic Breast Cancer

NCT03424005

Clinical

Trials by Indication[1]

Metastatic Breast Cancer2 trials

A Phase 1b Open-Label Multicenter Study of OP-1250 (Palazestrant) in Combination With the CDK4/6 Inhibitor Ribociclib, With the PI3K Inhibitor Alpelisib, With the mTOR Inhibitor Everolimus, or With CDK4 Inhibitor Atirmociclib in Adult Subjects With Advanced and/or Metastatic ER Positive, HER2 Negative Breast Cancer

Active, not recruiting·OOlema Pharmaceuticals, Inc.·Phase 1·NCT05508906·190 enrolled

A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (Morpheus-panBC)

Recruiting· Roche logo

Roche·Preclinical·NCT03424005·1,132 enrolled

Advanced Breast Cancer1 trial

A Phase IIa, Open-label Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of Camizestrant in Combination With Atirmociclib in Participants With ER-positive, HER2-negative Advanced Breast Cancer (SERENA-1b)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT07427394·24 enrolled

Hepatic Impairment1 trial

A PHASE 1, NON-RANDOMIZED, OPEN-LABEL, SINGLE-DOSE, PARALLEL GROUP STUDY TO COMPARE THE PHARMACOKINETICS OF ATIRMOCICLIB IN ADULT PARTICIPANTS WITH VARYING DEGREES OF HEPATIC IMPAIRMENT RELATIVE TO PARTICIPANTS WITH NORMAL HEPATIC FUNCTION

Recruiting· Pfizer logo

Pfizer·Phase 1·NCT07677358·28 enrolled

Advanced Cancer1 trial

PIKture-01: First-in-Human Study of the PI3KαH1047R Mutant-Selective Inhibitor OKI-219 as Monotherapy in Participants With Advanced Solid Tumors and as Part of Combination Therapy in Participants With Advanced Breast Cancer

Active, not recruiting·OOnKure, Inc.·Phase 1·NCT06239467·200 enrolled

Unspecified1 trial

A PHASE 1, OPEN-LABEL, TWO-PERIOD, CROSS-OVER STUDY TO EVALUATE DOSE PROPORTIONALITY OF ATIRMOCICLIB (PF-07220060) PHARMACOKINETICS WHEN ADMINISTERED UNDER FED CONDITIONS TO HEALTHY PARTICIPANTS

Completed· Pfizer logo

Pfizer·Phase 1·NCT07215078·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Atirmociclib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Atirmociclib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Atirmociclib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Pfizer

Atirmociclib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Q1 2028

Q3 2030

Trials by Indication[1]

Metastatic Breast Cancer2 trials

Advanced Breast Cancer1 trial

Hepatic Impairment1 trial

Advanced Cancer1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News